Baccidal

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Baccidal

Quick Facts About Baccidal

Property Description
Active Ingredient Norfloxacin (INN)
Form Film-coated tablet
Pharmacological Class Fluoroquinolone Antibiotic
General Purpose Anti-infective / Treatment of bacterial infections
Origin Synthetic

What Type of Medicine is Baccidal? (Definition and Classification)

Baccidal is a prescription-only medication primarily classified as an antibiotic used to manage various infections caused by susceptible bacteria. Its active component belongs specifically to the fluoroquinolone pharmacological class, a group of powerful, chemically synthesized antibacterial agents. Baccidal is typically presented as an oral tablet, a distinguishing film-coated form designed for systemic administration, meaning the active substance is absorbed to work throughout the body against the infection. This class of antibiotics provides a broad-spectrum profile, making it effective against a wide variety of bacterial pathogens.


What is the Active Ingredient in Baccidal and Its Origin? (Composition and Origin)

The core therapeutic component of Baccidal is the single active ingredient, Norfloxacin, a first-generation fluoroquinolone. Baccidal is a synthetic medicine, meaning Norfloxacin is produced through chemical synthesis in a laboratory rather than being derived from natural sources, such as molds or soil bacteria. This single-ingredient product composition ensures that the product’s therapeutic effect is traceable directly to the action of the fluoroquinolone compound, confirming its identity as a targeted, highly specific anti-infective agent. Norfloxacin functions by interfering with essential bacterial DNA processes.


What is the General Purpose of Baccidal? (High-Level Benefit)

The general purpose of Baccidal is to function as a potent anti-infective tool intended to resolve existing bacterial illnesses, such as those that may occur in the urinary tract. It achieves this primarily through its bactericidal effect, which means the drug actively destroys the bacterial cells rather than merely inhibiting their growth. This mechanism, characteristic of the fluoroquinolone class, allows Norfloxacin to target and stop the essential biological processes bacteria need to repair and replicate their DNA, leading to their complete elimination and ultimately aiding in the resolution of the infection.

What side effects are possible with Baccidal?

Possible Side Effects and Safety Information for Baccidal (Norfloxacin)

The official safety profile of Baccidal is structured by governmental regulatory authorities based on clinical data and reports, detailing adverse reactions by frequency and physiological system.

Documented Adverse Reactions

The most frequently reported side effects in official labeling are classified as Common (1/100 to < 1/10) and include nausea, headache, dizziness, and somnolence. Adverse reactions classified as Uncommon (1/1,000 to < 1/100) include insomnia, abdominal pain, rash, and temporary elevations in liver enzyme levels. Less frequent, Rare effects (1/10,000 to < 1/1,000) documented in regulatory sources include tendon rupture, photosensitivity, depression, and convulsions.

Adverse effects are categorized by the System-Organ-Class (SOC) they affect, which notably includes Gastrointestinal disorders, Nervous system disorders, Psychiatric disorders, Musculoskeletal and connective tissue disorders, and Cardiac disorders.

Serious Adverse Reactions and Safety Constraints

The regulatory documentation highlights several potentially disabling and serious adverse reactions associated with systemic fluoroquinolones. These include tendon rupture (often the Achilles tendon), peripheral neuropathy (nerve damage), seizures, and Aortic Aneurysm and Dissection. These serious effects may occur during treatment or up to several months after completion, a timing pattern noted in the label.

Baccidal is formally contraindicated in specific groups, including children and growing adolescents due to the risk of articular cartilage damage. Its use is also contraindicated in individuals with a history of tendon disorders related to prior fluoroquinolone exposure and during pregnancy and lactation.

Overdose and Emergency Response

Overdose and when to seek help

This section describes the documented clinical signs and mandated emergency actions for Norfloxacin (Baccidal) overdose, as specified in authoritative government regulatory information.


Documented Overdose Manifestations

Official labeling indicates that an overdose or significant poisoning may present with a cluster of effects. Documented gastrointestinal effects include vomiting, diarrhea, and gastrointestinal hemorrhage. Central Nervous System (CNS) manifestations that have been reported include dizziness, ringing in the ears (tinnitus), and convulsions (seizures).

In cases of significant poisoning, the potential for severe, organ-level complications is noted, specifically acute renal failure and liver damage.


Required Emergency Actions

The regulatory guidance mandates that treatment for Norfloxacin overdose is symptomatic and supportive, as no specific antidote is known. Hospital monitoring is required in cases of significant poisoning. Procedures such as gastric lavage or the administration of activated charcoal may be considered following the ingestion of a potentially life-threatening quantity.


When to Seek Immediate Medical Attention

Seek immediate medical attention is the mandated action if an overdose is suspected, or if any severe, potentially life-threatening reactions—such as signs of anaphylaxis, tendon issues, or severe neurological symptoms like convulsions—are observed, as stated in the official prescribing information. Patients with impaired renal function are recognized as having an increased risk of systemic exposure.

Therapeutic Uses of Baccidal

The primary role of Baccidal is to offer supportive, short-term relief for symptoms associated with specific bacterial conditions, helping patients regain comfort and stability during difficult periods. This therapeutic application is focused on situations involving certain distressing symptoms associated with conditions presenting with systemic or localized discomfort.


Easing Episodic Symptom Discomfort

Baccidal is applied across domains where additional symptomatic support is needed, such as conditions presenting with systemic or localized discomfort. It is relevant for easing symptoms related to systemic imbalance or irritative states and is used when groups of symptoms appear suddenly or fluctuate. It is relevant for managing symptoms that interfere with daily comfort.

Quick Fact: Support for Disruptive Symptom Clusters.


Managing Heightened Distress and Functional Strain

This medicine is commonly used across conditions presenting with acute episodes where symptoms may intensify temporarily, and functional stability becomes affected. It helps address symptom clusters that create noticeable functional strain and assists with maintaining stability during phases of increased distress or discomfort. Baccidal provides support that helps ease the overall symptom burden when symptoms become more noticeable.


Supportive Care for Disruptive Manifestations

Baccidal plays a role in managing conditions characterized by periods of heightened symptoms and is relevant when supportive symptom management is appropriate. It is commonly used when short-term symptomatic assistance is needed to help patients cope more steadily with difficult episodes, thereby assisting with the management of symptoms that create noticeable physiological strain.

Regulatory References

  1. Ficha técnica BACCIDAL (Norfloxacino)

Eligibility and Restrictions for Use

Official Eligibility and Contraindications for Baccidal (Norfloxacin)

Baccidal use is governed by strict regulatory rules defining the eligible population and those for whom the medicine is contraindicated.

Population Status Regulatory Status
Adult Patients Generally eligible for use [FDA/EMA].
Children/Adolescents (Under 18) Contraindicated or Not Recommended [SmPC/Health Canada].
Pregnant/Lactating Women Contraindicated or Not Recommended [SmPC/TGA].

Absolute Contraindications

The medicine is strictly contraindicated in persons with a history of hypersensitivity to Norfloxacin or any other quinolone antibiotic. Patients with a known history of tendinitis or tendon rupture associated with prior quinolone use, or those with a known history of Myasthenia Gravis, must not use this medicine.

Conditional Use Restrictions

Use is restricted and requires careful consideration in adult patients with severe renal impairment; official labels mandate a dose adjustment for this population. Caution is also necessary for patients with certain CNS disorders (e.g., history of convulsions) and those with risk factors for QTc prolongation (heart rhythm changes), as stated in official labeling.

This structure reflects the regulatory classification of Norfloxacin, which establishes eligibility based on age, reproductive status, prior drug-related injuries, and specific comorbidities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Baccidal (Norfloxacin) possesses officially documented interaction patterns that are classified by regulatory authorities based on pharmacokinetic, pharmacodynamic, and physical absorption mechanisms.

Pharmacokinetic and Exposure Interactions

The most critical constraint is the formal contraindication of co-administering Baccidal with Tizanidine, a restriction based on the risk of significantly increased plasma levels of Tizanidine. Baccidal is an officially recognized in vitro inhibitor of the CYP1A2 enzyme, which can lead to the reduced clearance and elevated serum concentrations of co-administered substrates such as Theophylline and Caffeine. Monitoring of drug levels is officially required for agents like Cyclosporine due to the risk of elevated serum levels, and Probenecid diminishes the urinary excretion of Norfloxacin.

Pharmacodynamic Interactions

Baccidal may enhance the effects of oral anticoagulants, including Warfarin, requiring close surveillance of Prothrombin time. Co-administration with NSAIDs like Fenbufen may increase the risk of CNS stimulation and convulsive seizures. Caution is advised when used with agents that prolong the QTc interval due to potential additive effects, and the use with Glyburide has been reported to result in severe hypoglycemia.

Absorption and Timing Rules

Products containing polyvalent cations (e.g., iron, magnesium, aluminum) found in antacids, sucralfate, or supplements significantly reduce Norfloxacin absorption. Regulatory timing rules mandate that these cation-containing products must not be taken within 2 hours of Baccidal. Similarly, dairy products and meals reduce absorption and require at least 1 hour before or 2 hours after administration.

Mechanism of Action

Interaction with Bacterial DNA Processing Enzymes

Baccidal, which contains the active ingredient Norfloxacin, functions through interaction with key bacterial enzymes involved in genetic material management. The compound acts as an inhibitor of DNA gyrase (Topoisomerase II) and Topoisomerase IV, which are vital enzymes in the bacterial cell. DNA gyrase manages DNA supercoiling necessary for replication, while Topoisomerase IV separates replicated chromosomes. By binding to and inhibiting these targets, the drug modifies early molecular steps in the DNA processing cascade.


Mechanism of Cellular Demise

The compound demonstrates differential affinity for the microbial enzymes compared to mammalian topoisomerases, directing the mechanistic effect toward the bacterial pathway. This inhibition prevents proper DNA supercoiling and segregation, influencing feedback regulation within the bacterial cell. This disruption of essential enzyme function leads to catastrophic double-stranded DNA breaks and subsequent cellular demise.

Dosage and Administration Information

General Administration Guidelines

Baccidal (Norfloxacin) is administered via the oral route using its 400 mg film-coated tablet form for the systemic delivery of the anti-infective agent. The usage protocol for most indications, such as urinary tract infections, involves a standard dose of 400 mg taken twice daily (every 12 hours). For certain specific, acute infections, a single 800 mg dose may be used, but the total daily amount must not exceed 800 mg.

Proper administration requires careful time separation from certain substances to optimize drug absorption. The tablet is taken at least one hour before or two hours after consuming a meal, milk, or any other dairy products. Furthermore, Norfloxacin is not to be co-administered with iron, zinc, aluminum, or magnesium-containing products, such as antacids or multivitamins; a minimum two-hour window of separation is necessary before or after these items. Each dose is taken with a full glass of water, and it is standard to maintain adequate fluid intake throughout the course.


The duration of use varies and depends on the specific condition being addressed, ranging from as short as 3 days for select uncomplicated infections to 10–21 days for complicated cases, and extending up to 28 days or more for chronic prostatitis. A modification to the standard schedule is used for patients with significant renal impairment; in such cases, the dosage is typically adjusted to 400 mg taken once daily. It is standard practice to complete the full, prescribed course of treatment, regardless of symptom resolution.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Baccidal

Evidence for use in Uncomplicated Urinary Tract Infections (UTI)

Research has primarily examined Baccidal's use in the context of conditions characterized by acute or disruptive episodes, specifically uncomplicated urinary tract infections (UTIs) in adults. The available evidence includes short-term Randomized Controlled Trials (RCTs). These studies were evaluated in comparisons of Baccidal to a placebo or to other compounds that were evaluated in these infections. Researchers explored outcomes related to physiological strain or stress, such as data points captured concerning painful urination or the frequency of bathroom visits.

Studies report patterns observed when Baccidal was studied in women experiencing these conditions. The findings indicate that in the observed populations, research highlights changes measured during the study period in symptom patterns. However, the exact way that "clinical clearance" was defined was inconsistent. This evidence contributes to the broader evidence landscape but makes direct synthesis complex.

Evidence for use in Preventing Spontaneous Bacterial Peritonitis (SBP)

Baccidal was studied for the research scenario of reducing the occurrence of a type of infection called Spontaneous Bacterial Peritonitis (SBP) in adult patients with cirrhosis and ascites. The evidence here stems from Randomized Controlled Trials (RCTs) and meta-analyses evaluating patients with conditions presenting with cycles of stability and flare-ups. Research examined whether Baccidal use was associated with a change in the frequency of SBP diagnosis.

Findings were mixed regarding certain critical outcomes, and the data show patterns related to survival rates that were not uniformly distinct between all study groups. This means certainty remains low regarding long-term health patterns in this patient group with underlying liver disease.

What is Still Uncertain About Baccidal Research

Key uncertainties include that long-term effects are not fully established across all indications. Evidence quality varies across studies, and data for certain groups remain insufficient for many special populations, such as pediatric patients or those with severe multi-organ dysfunction, to fully characterize the research profile.

Key Studies & References

  1. Comparative effectiveness of oral antibiotic regimens for urinary tract infections in outpatients: a systematic review
  2. Efficacy of Norfloxacin Prophylaxis to Prevent Spontaneous Bacterial Peritonitis: A Systematic Review and Meta-Analysis
  3. Review of Norfloxacin in Complicated and Recurrent Urinary Tract Infections

Frequently Asked Questions (FAQ)

Common questions about Baccidal (FAQ)


Q: What is the main difference between Baccidal and standard antibiotics?

A: Baccidal belongs to the fluoroquinolone antibiotic class, making it chemically distinct from many other antibiotic families. Its action is bactericidal, meaning it disrupts the systems that bacteria need to manage their genetic material and survive. Official labeling indicates this drug targets two specific bacterial enzymes.


Q: Is Baccidal used to treat all types of infections?

A: No, Baccidal is an anti-infective medicine intended exclusively to resolve illnesses caused by susceptible bacteria. Official product information confirms that it is not effective against infections caused by other types of organisms, such as viruses or fungi.


Q: Is Baccidal safe to take for a long time?

A: The duration of Baccidal treatment can vary widely, from a few days up to 28 days or more, depending on the specific infection. Studies and official information also indicate that the long-term effects are not fully established across all approved indications.


Q: Why is Baccidal prescribed for [specific condition] and not [similar condition]?

A: The use of Baccidal is governed by official use guidelines that determine the drug’s approved indications. It is prescribed as an anti-infective only for specific bacterial illnesses where the organisms are confirmed to be susceptible to the drug’s action.


Q: What is the risk of having a severe allergic reaction to Baccidal?

A: Official labeling notes that a history of hypersensitivity (severe allergic reaction) to Baccidal or other quinolone antibiotics is an absolute contraindication. Therefore, the use of Baccidal is formally contraindicated in individuals with such a history.


Q: Is Baccidal a strong medication?

A: Regulatory documents describe Baccidal as a powerful and potent anti-infective agent. It is classified as a prescription-only medication within the fluoroquinolone antibiotic class, reflecting its use for treating bacterial infections.


Q: Can older adults safely take Baccidal?

A: Official eligibility criteria confirm that adult patients are generally eligible for the use of Baccidal. The regulatory labeling does not place specific age-based restrictions on older adults, but certain conditions, such as severe renal impairment, require special consideration from a healthcare professional.


Q: Is Baccidal associated with any long-term health risks?

A: Serious adverse reactions, such as tendon rupture and nerve damage known as peripheral neuropathy, have been documented to occur up to several months after treatment completion. Official research summaries also state that the long-term effects are not fully established across all approved uses.


Q: Are there any religious or dietary restrictions related to Baccidal?

A: The official administration rules establish a requirement that Baccidal be taken separately from dairy products and meals to optimize drug absorption. Regulatory documents do not contain information regarding religious restrictions related to the drug’s use.


Q: Can Baccidal be taken by individuals with known heart conditions?

A: Official product information notes that certain patient risk factors, such as those for QTc prolongation (a change in heart rhythm), require careful consideration before prescribing. The safety profile also includes Cardiac disorders in its system-organ classification.


Q: What is the mechanism of action of Baccidal in simple terms?

A: Baccidal works at the cellular level by blocking essential enzyme systems within the bacteria. This mechanism prevents the bacteria from copying and repairing their DNA, leading to a disruption in the bacteria's life cycle.


Q: What should I do if the side effects of Baccidal feel severe?

A: Official safety information documents the existence of potentially disabling and serious adverse reactions. These reactions include tendon rupture and peripheral neuropathy (nerve damage), which may occur during the course of treatment or up to several months after completion. This information highlights the severe nature of certain potential effects.


Q: Can Baccidal be crushed or chewed?

A: Baccidal is formulated as a film-coated tablet intended for administration via the oral route. Official regulatory labeling does not provide specific instructions for altering the tablet's form, such as crushing or chewing.


Q: Does Baccidal have a warning about driving or operating machinery?

A: Because common side effects include dizziness and somnolence (drowsiness), the presence of these central nervous system effects leads to regulatory warnings regarding the performance of tasks that require mental alertness, such as driving or operating heavy machinery.


Q: How is Baccidal different from a probiotic?

A: Baccidal is a synthetic, prescription-only antibiotic (fluoroquinolone class) that is intended to disrupt the life cycle of susceptible bacteria. A probiotic is not a drug; it is a substance that typically introduces live microorganisms to potentially benefit the host.


Q: What specific ingredients are in Baccidal besides the active component?

A: Baccidal is defined in regulatory documents as a single-ingredient product containing only the active component, Norfloxacin. Information regarding the inactive ingredients (or excipients) is not detailed in the summary regulatory information provided.


Q: What should I tell my doctor about before starting Baccidal?

A: Official documents specify certain historical medical conditions that are required for consideration when prescribing Baccidal. These conditions include a history of hypersensitivity to any quinolone antibiotic, previous tendon disorders related to quinolone use, or a known history of Myasthenia Gravis.

How should Baccidal be stored and disposed of?

Storage and Disposal of Baccidal (Norfloxacin)

The official labeling for Baccidal (Norfloxacin) film-coated tablets defines specific storage and disposal requirements to ensure product integrity and public safety.

Storage Conditions

Baccidal must be stored at room temperature, generally defined as not exceeding 30°C. It is required to keep the tablets in the original container and maintain it tightly closed to protect the medicine from excessive moisture. The container must be kept out of the sight and reach of children as a mandatory safety measure.

Disposal Instructions

Unused or expired Baccidal should not be disposed of in household trash or wastewater. Regulatory documents mandate that disposal must occur through official drug take-back programs or government-approved collection points, in accordance with local environmental regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Baccidal found in:

A-Z Index: